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An extensive molecular analysis of the CF transmembrane regulator (CFTR) gene was performed to establish the CFTRmutation
spectrumand frequencies in the Palestinian population, which can be considered as an understudied population.Weused a targeted
Next Generation Sequencing approach to sequence the entire coding region and the adjacent sequences of theCFTR gene combined
with MLPA analysis of 60 unrelated CF patients. Eighteen different CF-causing mutations, including one previously undescribed
mutation p.(Gly1265Arg), were identified. The overall detection rate is up to 67%, and when we consider only CF patients with
sweat chloride concentrations >70mEq/L, we even have a pickup rate of 92%. Whereas p.(Phe508del) is the most frequent allele
(35% of the positive cases), 3 othermutations c.2988+1Kbdel8.6Kb, c.1393-1G>A, and p.(Gly85Glu) showed frequencies higher than
5% and a total of 9 mutations account for 84% of the mutations. This limited spectrum of CF mutations is in agreement with the
homozygous ethnic origin of the Palestinian population. The relative large portion of patients without a mutation is most likely
due to clinical misdiagnosis. Our results will be important in the development of an adequate molecular diagnostic test for CF in
Palestine.
1. Introduction
Cystic fibrosis (CF) is a severe life threatening genetic disease
most common among Caucasians with an incidence ranging
from 1 in 2500 to 1 in 3600 [1]. CF is inherited in an autosomal
recessive way and the cystic fibrosis transmembrane conduc-
tance regulator gene (CFTR), located on chromosome 7q31.2
[2], has been identified as the responsible gene encoding a
transmembrane protein that functions as a chloride channel
and a regulator of other channels across the epithelial cell
membrane. The defective protein impairs water movement
across epithelia leading to formation of viscous mucus that
obstructs the airways of the lungs and ducts of the pancreas.
CF is characterized by progressive lung disease, pancreatic
dysfunction, elevated sweat electrolytes, and male infertility
[3].
So far, more than 1900 different CFTR mutations have
been reported [4]. Although most mutations are rare, the
three-base-pair deletion p.(Phe508del) is most common in
the Caucasian population affecting about 70% of the patients
whereas in the Jewish population the p.(Trp1282∗) is themost
prevalent with a frequency of 60% [5], clearly indicating that
the occurrence of mutations is highly population specific.
For many ethnic or geographic populations, the mutation
spectrum has been determined [6–15].
Recently, CF has been diagnosed in the Middle East
ranging from 1 in 2,500 to 1 in 16,000 with different mutation
frequencies according to the ethnic origin of populations
[16]. However, reliable information about the frequency of
CF among the Palestinians is still lacking and the spectrum
and nature of mutations have not been documented yet ham-
pering molecular diagnostics. A good insight into the nature
and frequency of the mutations in a specific population is a
prerequisite to set up adequate and cost-effective molecular
diagnostics.
The aim of this study was to determine the CF mutation
spectrum among the Palestinian patient population. Samples
from 60 unrelated CF patients residing in the West Bank
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and Gaza were collected and their respective CF mutations
were determined. Consequently, the mutation spectrum was
compared with other ethnic groups residing in the Arabic
population.
2. Materials and Methods
2.1. Patients and Sample Collection. A total of 60 unrelated
Palestinian CF patients, 19 of them residing in theWest Bank
and 41 residing in Gaza, participated in this study of which 34
are males and 26 are females. Most of the participants (97%)
were children less than 18 years old. The criteria for inclusion
in this study were based on the clinical diagnosis. Typi-
cal pulmonary and/or gastrointestinal tract manifestations
and/or elevated sweat chloride values (>60mEq/L, Table 1)
were the main criteria. Whole blood (3mL) was collected in
EDTAvacutainer tubes (BD). Participation in this projectwas
based on the free will of the participants. Signed consent was
obtained from each participant and/or the guardian.
2.2. DNA Extraction and Polymerase Chain Reaction (PCR).
Genomic DNA was extracted and purified from whole
EDTA-blood by the automated extraction apparatus Autop-
ure LS (Qiagen) using the PureGene DNA Purification Kit
(Qiagen).
Amplification of the coding region and flanking introns
of the CFTR gene was conducted using the 2720 thermal
cycler (Applied Biosystems). A total of 28 sets of primers
were developed, flanking at least 25 intronic nucleotides
away from each of the 27 exons of the CFTR gene.
Primers are found in supplemental Table 1 (see supple-
mental Table 1 in Supplementary Material available online
at http://dx.doi.org/10.1155/2015/458653). Amplification was
performed with 2.5 𝜇L of the purified DNA (50 ng/𝜇L) tem-
plate in a total of 10 𝜇L reaction mixture. The complete mix
constituted the following components: 5𝜇L of 2X KAPA2G
Robust Hot Start Ready Mix (Kapa biosystems), 1.25𝜇L
upstream primer (0.1 𝜇M), and 1.25 𝜇L downstream primer
(0.1 𝜇M). The following amplification conditions were used:
95∘C for 3min and then 95∘C for 15 sec, 60∘C for 10 sec, and
72∘C for 15 sec, for 32 cycles, with final extension at 72∘C
for 1min. The LabChip GX (PerkinElmer, USA) capillary
electrophoresis was used to assess PCR product.
2.3. NGS Sequencing. For each patient, all PCRproducts were
pooled equimolary before they entered the Nextera sample
preparation protocol (Nextera XT DNA Sample Prep Kit
(Illumina, Inc., San Diego, CA)), followed by 250 bp single-
end sequencing on a MiSeq instrument (Illumina, Inc., San
Diego, CA). All 60 samples were labeled using 60 different
index tags (Nextera, Epicentre Biotechnologies).
2.4. Data Analysis. Reads were aligned to the human genome
(hg19/GRC37) using the CLCBio software package (CLC
GenomicsWorkbench 6.0.2). All exons with a coverage lower
than 20 were analysed by Sanger sequencing. We first filtered
all variants classified as deleterious according to the CFTR
mutation database (ENST00000003084) [4]. To identify new
Table 1: Patients data and sweat chloride concentrations.
# Age(years) Sex Region
Sweat chloride
values (mEq/L)
P1 1 M Gaza 113
P2 3 M Gaza 85
P3 8 M Gaza 111
P4 11 M Gaza 70
P5 11 F Gaza 60
P6 5 F Gaza 100
P7 8 F Gaza 66
P8 3 M Gaza 103
P9 <1 M Gaza 81
P10 1 M Gaza NR
P11 7 M Gaza QNS
P12 10 M Gaza 72
P13 8 M Gaza 90
P14 4 M Gaza 60
P15 6 M Gaza NR
P16 7.5 M Gaza 90
P17 7 M Gaza 96
P18 6 F Gaza 76
P19 4 F Gaza 114
P20 4 F Gaza 118
P21 1 M Gaza 77
P22 1 F Gaza 114
P23 10 M Gaza 100
P24 3 M Gaza 126
P25 2 M Gaza 129
P26 9 F Gaza 105
P27 18 M Gaza 42
P28 11 F Gaza 128
P29 6 M Gaza 135
P30 5 F Gaza QNS
P31 13 M Gaza 106
P32 15 M Gaza 60
P33 3 M Gaza 107
P34 9 M Gaza 46
P35 17 F Gaza 64
P36 1.5 F Gaza 129
P37 7 M Gaza NR
P38 2 F Gaza QNS
P39 13 F Gaza 54
P40 10 M Gaza 62
P41 4 M Gaza 70
P42 7 M West Bank 117
P43 18.5 M West Bank 121
P44 5 M West Bank 105
P45 13 M West Bank 100
P46 12 M West Bank NR
P47 12 M West Bank 110
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Table 1: Continued.
# Age(years) Sex Region
Sweat chloride
values (mEq/L)
P48 7 M West Bank 108
P49 8 F West Bank 105
P50 7 F West Bank NR
P51 15 F West Bank NR
P52 2 F West Bank NR
P53 10 F West Bank 87
P54 12 F West Bank 104
P55 2.5 F West Bank 110
P56 12 F West Bank 112
P57 31 M West Bank 120
P58 3 F West Bank 103
P59 15 F West Bank 45
P60 30 M West Bank NR
NR: no result, used to indicate nonreported results.
QNS: quantity not sufficient, used to indicate insufficient sweat samples to
perform the sweat test.
mutations the data were filtered against dbSNP135 (MAF >
1%). For novel variants, causality was assessed using in silico
prediction software (Alamut, Interactive Biosoftware, Rouen,
France).
2.5. Mutation Confirmation. Mutations were confirmed with
the INNO-LiPA CFTR17 and CFTR19 kit (Fujirebio, Europe)
which provides probes for the 35 most frequent CFTR-
related mutations worldwide or by Sanger sequencing. Direct
sequencing of the PCR product was performed on an
ABI3130XL sequencer (Applied Biosystems, Inc., Foster City,
CA). For the larger deletions or insertions and for all patients
with only one or no mutation, multiple ligation-dependent
probe amplification (MLPA) analysis was applied (MRC-
Holland, SALSA MLPA KIT P091-D1 CFTR).
3. Results
3.1. NGS Analysis. We applied an NGS screening strategy to
efficiently identify causative mutations in the 60 unrelated
Palestinian patients with a clinical diagnosis of CF. Approx-
imately, 98% of all reads on the MiSeq were successfully
mapped to the reference genome. The overall mean read
depth in the target area was 344x. A read depth of 10x for 92%
of the bases and 20x for 90%of the baseswas obtained. Patient
P9 had the best coverage with all amplicons covered with at
least 20x whereas patient P7 had the lowest number of ampli-
cons (13) with a coverage higher than 20x (data not shown).
3.2. Identification of Causative Mutations. We identified 17
differentmutations in 40 patients which have previously been
described as CF-causing mutations, including 3 splice sites, 5
missense mutations, 4 frame shift mutations, 3 stopcodons,
and 2 exon spanning deletions (Table 2). A homozygous
exon-spanning deletion was suspected when we were unable
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Figure 1:CFTRmutation spectrum among Palestinians inGaza and
West Bank.
to amplify the exons 19, 20 and 21 by PCR and consequently
we did not obtain any read for these amplicons by NGS. The
presence of the deletion was confirmed by MLPA analysis.
In addition we identified one novel potentially deleterious
homozygous missense mutation p.(Gly1265Arg) (phyloP:
5.53, Grantham dist.: 125, Sift: Deleterious, Mutation Taster:
disease causing). The NGS approach does not allow, at least
with the PCR-enrichment approach applied in this strat-
egy, detection of large heterozygous deletions or insertions.
Therefore, we further investigated the remaining 19 negative
patients and the 3 heterozygous patients for the presence of
deletions/insertions using MLPA analysis. This revealed two
heterozygous deletions in patients P24 and P49. In total, we
were able to detect 81 CFTRmutations on a total of 120 alleles
from 60 CF patients. Mutations were compared between CF
patients originating from the West Bank and those from
Gaza, as both regions are physically divided over 66 years.
Data are represented in Figure 1.
4. Discussion
This is the first study to investigate the CFTRmutation spec-
trum in the Palestinian population that was conducted on 60
unrelated CF patients residing in the West Bank and Gaza,
Palestine. We identified in 41 of these probands 81 CFTR
mutations of which 18 are different. All patients are homozy-
gous or compound heterozygous, except patient 18, in whom
we identified only one singlemutation.Thismay be explained
by the fact that the technology used in this approach does
not allow detection of deep intronic mutations. The five
most common mutations are p.(Phe508del) followed by the
deletion of exons 19–21 (c.2988+1Kbdel8.6Kb), c.1393-1G>A,
p.(Gly85Glu), and p.(Lys684Serfs∗38), representing 67% of
all mutations (Figure 1). The homozygous p.(Gly1265Arg)
mutation, which we identified in an 8-year-old male from
Gaza, was never reported before. Comparing our results with
a study conducted in Israel by Laufer-Cahana et al. [17]
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Table 2: CFTRmutations among Palestinians in Gaza and West Bank.
c-notation p-notation Exon/intron dbSNP # # of patientsGaza
# of patients
West Bank Patient(s)
del exon2 Exon 2 1 1 24 (het), 43
c.223C>T p.(Arg75∗) Exon 3 121908749 1 13
c.254G>A p.(Gly85Glu) Exon 3 75961395 4 44 (het), 56, 57 (het),58
c.1040G>C p.(Arg347Pro) Exon 8 77932196 1 33
c.1209+1G>A Intron 9 397508176 1 2
c.1393−1G>A Intron 10 397508200 4 42, 47, 54, 55 (het)
c.1521 1523delCTT p.(Phe508del) Exon 11 113993960 11 5
1, 3, 9, 11, 17, 19, 22
(het), 23, 24 (het), 28
(het), 29, 46, 48, 49
(het), 50, 52
c.1585−1G>A Intron 11 76713772 2 26, 31
c.1624G>T p.(Gly542∗) Exon 12 113993959 1 28 (het)
c.2051 2052delAAinsG p.(Lys684Serfs∗38) Exon 14 121908799 2 8, 25
c.2089 2090insA p.(Arg697fs) Exon 14 397508341 1 22 (het)
c.2988+1Kbdel8.6Kb Exons 19, 20, 21 4 1 10, 20, 21, 36, 49 (het)
c.3299A>C p.(Gln1100Pro) Exon 20 397508535 1 57 (het)
c.3793G>A1 p.(Gly1265Arg) Exon 23 1 16
c.3808G>A p.(Asp1270Asn) Exon 23 11971167 1 18 (het)
c.3846G>A p.(Trp1282∗) Exon 23 77010898 2 55 (het), 60
c.3909C>G p.(Asn1303Lys) Exon 24 80034486 2 44 (het), 51
c.4251delA p.(Glu1417fs) Exon 27 397508706 1 6
1Previously undescribed mutation.
All mutations are homozygous except those indicated by (het).
In patients P4, P5, P7, P12, P14, P15, P27, P30, P32, P34, P35, P37, P38, P39, P40, P41, P45, P53, and P59 no mutation was detected.
In P18 only one mutation was detected.
among Israeli Arab patients showed similar rates for
mutations p.(Phe508del) (34%), p.(Gly85Glu) (8%), and
p.(Lys684Serfs∗38) (8%) and the deletion of exons 19–21 dele-
tion (c.2988+1Kbdel8.6Kb) (13%), confirming the common
origin of both populations. Interestingly, whereas the rate of
the p.(Phe508del) mutation is similar to that in the neighbor-
ing Lebanese CF population and the Jewish CF populations
from Balkani (Turkish and Greeks) and Ashkenazi origins
[1, 15], the deletion of exons 19–21 (c.2988+1Kbdel8.6Kb) was
only present in PalestinianArabswhichmay indicate that this
mutation is a founder mutation among this population [18,
19].The twomutations p.(Gly85Glu) and c.1585-1G>A, which
were identified in this study, were also found among the
Jewish CF populations from Balkani (9.5%) and Ashkenazi
(1%) origins, respectively [15]. On the other hand, one of
the most frequent mutations in the Jewish CF population
p.(Trp1282∗) (31%) was found to be less frequent in this
study (4%), similar to other Arabic CF populations such
as Tunisians (4.4%) and Algerians (4.2%) [8, 9, 15]. The
rate of the p.(Asn1303Lys) mutation was about the same in
Ashkenazi Jews and the Palestinian CF population tested
in this study (5%), as well as in the Iranian (4.3%) and
Tunisian (6.6%) CF populations [8, 11, 15]. Designing an allele
specific primer based CF assay for the Palestinian population,
a technology that can be easily implemented in any diagnostic
setting, including the 9most frequentmutations, would result
in a test that identifies 84% of the Palestinian mutations.
The differences in the rates of mutations identified in
CF patients residing in the West Bank versus those in
Gaza, are remarkable. For example, mutations c.1393-1G>A,
p.(Gly85Glu), p.(Trp1282X), and p.(Asn1303Lys) were only
present among Palestinians in the West Bank, while muta-
tions p.(Lys684Serfs∗38) and c.1585-1G>A were only present
among Palestinians residing in Gaza (Figure 1). Interestingly,
the p.(Phe508del) mutation was primarily prevalent among
patients living in Gaza (68%) as compared to patients in the
West Bank (32%). This may be due to the heterogeneous
Arab population and the political barriers that were imposed
on this population for many decades limiting their freedom
of movement and concentrated the population into small
communities in different geographic areas.
NGS technology combined with MLPA analysis proved
to be a very efficient and cost-effective way to identify
CFTR mutations. It should be noticed that heterozygous
exon-spanning deletions or insertions are not observed
with the PCR-based enrichment strategy followed by NGS
analysis and therefore the combination of the NGS approach
with MLPA analysis is highly recommended. The mutations
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included in the INNO-LIPA CFTR17 and CFTR19 kit cover
only 66% of the mutations and therefore have a limited
diagnostic value for the Palestinian population.
The relatively low mutation detection rate of 67% of the
CF patients tested in this study is most likely caused by
clinical misdiagnosis depending on the sweat chloride test.
Values of this test can be influenced by nutritional state,
skin condition, age, and many other factors, resulting in false
positive sweat chloride values as high as 15% [20, 21]. All
patients, in whom CF mutations have been identified and for
whom a sweat chloride test has been performed, had a sweat
chloride value higher than 70mEq\L. On the other hand,
most patients without a mutation have sweat chloride values
lower or around 60mEq\L and therefore have a less likely
clinical diagnosis of cystic fibrosis. If we only consider the for-
mer group of patients, with a sweat chloride value higher than
70mEq\L, the mutation detection rate rises from 67 to 92%.
In conclusion, we identified the most common CF
mutations and their respective frequency in the Palestinian
population. Not only is this knowledge important for the
families themselves but also it is a prerequisite to set up a
reliable and sensitive diagnostic test for CF in this population.
Genetic testing in this area for recessive disorders is highly
recommended because of the high rates of consanguineous
marriages among the Palestinians (25%–65%) [22], resulting
in a high risk for genetic diseases including CF [23].
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